Skip to contentpdufa.bio

aleniglipron (oral small molecule GLP-1 RA)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

aleniglipron (oral small molecule GLP-1 RA) is a Structure Therapeutics Inc. program in obesity / chronic weight management. Its next catalyst is a Readout in Q4 2026.

GPCR catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indications under review: Obesity / chronic weight management; Obesity; type 2 diabetes. Sponsor: Structure Therapeutics Inc. (GPCR). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026GPCRReadout · Q4 2028GPCR

Specialist biotech funds holding GPCR, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Avoro Capital Advisors6,555,555$205.0 millionfiled November 16, 2026
BVF Inc.2,691,426$84.2 millionfiled November 16, 2026
RTW Investments2,282,138$71.4 millionfiled November 16, 2026
Baker Bros. Advisors1,432,529$44.8 millionfiled November 16, 2026
OrbiMed Advisors1,331,000$41.6 millionfiled November 16, 2026
Cormorant Asset Management30,000$938,100filed November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is aleniglipron (oral small molecule GLP-1 RA)'s next FDA decision or readout?

The next tracked catalyst for aleniglipron (oral small molecule GLP-1 RA) is a Readout in Q4 2026.

What happened at aleniglipron (oral small molecule GLP-1 RA)'s most recent FDA decision?

No FDA decision for aleniglipron (oral small molecule GLP-1 RA) is in our archive yet.

What is aleniglipron (oral small molecule GLP-1 RA) used for?

In our records aleniglipron (oral small molecule GLP-1 RA) is under review or in development for Obesity / chronic weight management; Obesity; type 2 diabetes.

Who makes aleniglipron (oral small molecule GLP-1 RA)?

Structure Therapeutics Inc. (GPCR).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.